The clinical presentation of *Legionella* arthritis reveals the mode of infection and the bacterial species: case report and literature review

Marine Ibranosyan1, Laetitia Beraud1,2, Hélène Lemaire3,4, Anne-Gaëlle Ranc1,2, Christophe Ginevra2,5,6,7, Sophie Jarraud1,2,5,6,7 and Ghislaine Descours1,2,5,6,7*

**Abstract**

**Background:** While *Legionella* is a common cause of pneumonia, extrapulmonary infections like arthritis are scarce. Here, we describe a case of monoarthritis due to *Legionella bozemanii*, with no history of pneumonia. We provide a literature review of the 9 previously published *Legionella* arthritis and highlight a dichotomous epidemiology suggesting different physiopathological pathways leading to joint infection.

**Case presentation:** A 56-year old woman under immunosuppressive treatment by oral and intra-articular corticosteroids, methotrexate, and tocilizumab for an anti-synthetase syndrome was hospitalized for worsening pain and swelling of the left wrist for 3 days. Clinical examination showed left wrist synovitis and no fever. The arthritis occurred a few days after an accidental fall on wet asphalt responsible for a cutaneous wound followed by a corticosteroid intra-articular injection. Due to both the negativity of conventional culture of articular fluid and suspicion of infection, 16S rRNA and specific PCRs were performed leading to the identification of *L. bozemanii*. *Legionella*-specific culture of the articular fluid was performed retrospectively and isolated *L. bozemanii*. The empiric antibiotic therapy was switched for oral levofloxacin and rifampin and the patient recovered after a 12-week treatment.

**Conclusion:** We report a case of *L. bozemanii* monoarthritis in an immunosuppressed woman, following a fall on wet asphalt and intra-articular corticosteroid injection. The review of the literature found that the clinical presentation reveals the mode of infection and the bacterial species. Monoarthritis more likely occurred after inoculation in patients under immunosuppressive therapy and were associated with non-*Legionella pneumophila* serogroup 1 (Lp1) strains that predominate in the environment. Polyarthritis were more likely secondary legionellosis localizations after blood spread of Lp1, the most frequently found in pneumonia. In both settings, 16S rRNA and *Legionella*-specific PCR were key factors for the diagnosis.

**Keywords:** *Legionella bozemanii*, Arthritis, Immunosuppression, Corticosteroid, Tocilizumab, Methotrexate, Inoculation, 16S rRNA PCR, Extrapulmonary infections
Background
Legionnaires’ disease (LD), a severe pneumonia caused by *Legionella*, represents 2–9% of cases of community-acquired pneumonia. There are more than 70 species and serogroups, but *Legionella pneumophila* serogroup 1 (Lp1) is responsible for more than 85% of cases of LD worldwide, while non-Lp1 infections occur more frequently in immunosuppressed patients [1]. Extrapulmonary infections, including arthritis, are scarce and not systematically related to pneumonia, suggesting a multifaceted infectious process. Herein, we report a case of *L. bozemanii* monoarthritis in an immunosuppressed woman, following a fall on wet asphalt and intra-articular corticosteroid (CS) injections.

Case presentation
A 56-year-old woman was hospitalized in the rheumatology department for worsening pain and swelling of the left wrist over the 3 preceding days. Her medical history included type 1 diabetes and anti-synthetase syndrome diagnosed 1 year previously and which was characterized by polyarthritis, dermatomyositis and interstitial lung disease, and treated by prednisone 10 mg/day, methotrexate (MTX) 20 mg/week, and tocilizumab. During the 2 previous months, she suffered from stage-II synovitis of the left wrist predominant at radiocarpal and middle carpal joints, associated with flexor and extensor digitorum communis tenosynovitis; she received 2 intra-articular injections of triamcinolone 2 months and 3 days before admission.

On admission, the patient showed left wrist synovitis with no fever. Clinical examination found a wound of the 3rd proximal interphalangeal joint, related to an accidental fall on wet asphalt 4 days before. The blood count and C-reactive protein were normal. Chest X-ray showed no worsening of the interstitial lung disease. Blood samples were collected for culture. Over the following days, while she remained afebrile, local symptoms worsened, with onset of a painful epityrochlear lymphadenopathy. On day 4, a septic arthritis was suspected and aspiration of the left wrist fluid was performed; hemorrhagic fluid with a white blood cell count of 15.7 G/L and a neutrophil count of 8.0 G/L (51%) was found. One sample was sent to the microbiology laboratory; Gram stain revealed no microorganism. An intravenous anti-staphylococcal antibiotic therapy (oxacillin 12 g/day, gentamicin 240 mg/day) was initiated. On day 6, routine wrist fluid culture remained sterile, 16S rRNA [2] and *Staphylococcus* PCRs were negative, and blood cultures also remained sterile. On day 9, while the patient had improved, an inflammatory aspect of the back of the hand and severe pain persisted. The antibiotic spectrum was broadened to piperacillin-tazobactam 12 g/day and vancomycin 2 g/day on infectiologist advice. On day 14, the patient had not improved and she underwent emergency surgery that found phlegmon of the F2 and F5 sheaths, requiring drainage and arthroscopic joint lavage. Six samples were sent to the microbiology laboratory; after 14 days of culture (day 28) a single *Lysinibacillus fusiformis* colony was found in 1 sample, and rare *Cutibacterium acnes* colonies in a second sample, which were considered as contaminants. On day 29, the 16S rRNA PCRs were positive for *Legionella* spp. for 2 of the 4 sterile samples. The 23S–5S PCR performed on these samples identified *L. bozemanii*. The antibiotic regimen was modified to a 12-week course of oral levofloxacin 1 g/day and rifampin 1.2 g/day, and the symptoms quickly resolved. The immunosuppressive therapy by prednisone and MTX was continued Fig. 1.

Retrospectively, the joint fluid sampled on day 4 also tested positive for *L. bozemanii* by 23S–5S PCR. Five specimens (1 collected on day 4, and 4 on day 14) were plated onto BCYE, BMPA and MWY plates (Oxoid, Dardilly, France). Only 1 day-14 sample grew *L. bozemanii* after 9 days. A *L. bozemanii* course of the infection.

Regarding the source of infection, no clinical or radiological pneumonia was diagnosed before or during the course of the infection. *L. bozemanii* inoculation from asphalt at the time of her fall was strongly suspected. We hypothesized that the immunosuppressive treatment contributed to development of the infection and delayed diagnosis.

Discussion and conclusions
When examining this case alongside those previously published and summarized in Table 1 (n = 9) [3–11], it is of note that *Legionella* arthritis was mostly identified incidentally by 16S rRNA PCR, which is consistent with the characteristics of the bacterium that does not usually grow on standard media. Interestingly, 2 clinical presentations can be distinguished. The first is monoarthritis (n = 7) that were all due to non-Lp1 strains and mainly reported in immunosuppressed patients (n = 6) with no history of pneumonia (n = 7); in 5 of the 7 cases, skin trauma close to the affected joint (n = 2) or an intra-articular injection or joint surgery (n = 3) was reported before arthritis. In contrast, cases of polyarthritis (n = 3) were all due to Lp1 and observed in patients with no immunosuppressive treatment who presented pneumonia at the time or before the diagnosis of arthritis. This dichotomous epidemiology suggests different physiopathological pathways leading to joint infection, which may result from both strain- and patient-related factors.

While more than 70 *Legionella* species have been isolated from freshwater and soil environments, less than half have been observed in clinical settings, and Lp1 is
Fig. 1 Timeline of interventions and outcomes

Diagnosis of an anti-synthetase syndrome (polymyositis, dermatomyositis, interstitial lung disease) treated by oral and intra-articular corticosteroids, methotrexate, and tocilizumab

- Day -3: Accidental fall on wet asphalt responsible for a cutaneous wound
- Day -2: Worsening pain, swelling of the left wrist
- Day 0: Clinical examination: left wrist synovitis without fever
- Day 0: Hospitalization
- Day 4: Worsening local symptoms, suspicion of septic arthritis
- Day 4: Aspiration of the left wrist fluid sent to the microbiology laboratory
- Day 4: Persistence of both inflammatory aspect of the back of the hand and severe pain
- Day 6: Phlegmon of the F2 and F5 sheaths, Drainage and arthroscopic joint lavage
- Day 6: Intravenous oxacillin 12g/day, gentamicin 240 mg/day
- Day 9: Routine wrist fluid culture sterile; 16S rRNA and Staphylococcus PCRs negative
- Day 9: Piperacillin-tazobactam 12g/day and vancomycin 2g/day
- Day 14: Negative conventional culture of articular fluid
- Day 28: 16S rRNA positive for *Legionella* spp
  - Specific PCR: *Legionella bozemanii*, confirmed by *Legionella*-specific culture
- Day 29: Levofloxacin 1g/day and rifampin 1.2g/day, 12-week course
- Day 113: Symptoms resolution

Resolution of the left wrist arthritis
Table 1  Demographic characteristics, clinical features, and microbiological diagnoses of the case reports of *Legionella* arthritis, including the current case

| Case                        | Gender | Age (y) | Localization     | Strain          | Microbiological diagnosis | Medical history                                      | Immunosuppressive treatment                  | Suspected origin of the infection | Pneumonia  |
|-----------------------------|--------|---------|------------------|-----------------|---------------------------|------------------------------------------------------|------------------------------------------|----------------------------------|------------|
| Current case                | Female | 56      | Left wrist       | *L. bozemanii*  | 16S rRNA PCR, culture    | Anti-synthetase syndrome                              | Oral and intra-articular CS, MTX, tocilizumab | Wound after fall on a wet asphalt | No         |
| Banderet et al. 2017 [3]    | Female | 90      | Left wrist       | *L. cincinnatiensis* | 16S rRNA PCR, culture | Presumed chondrocalcinosis, chronic kidney disease   | Oral and intra-articular CS                | Intra-articular CS injection         | No         |
| Just et al. 2012 [4]        | Female | 71      | Left knee        | *L. bozemanii*  | 16S rRNA PCR, culture    | Dermatomyositis                                       | Oral CS, MTX                            | Skin biopsy                      | No         |
| Fernández-Cruz et al. 2011 [5] | Female | 83      | Right knee       | *L. micdadei*   | 16S rRNA PCR, culture    | Rheumatoid arthritis                                  | Oral CS, MTX                            | Replacement of prosthesis the year before | No         |
| Fendrie et al. 2011 [6]     | Female | 58      | Right knee       | *L. dumoffii*   | 16S rRNA PCR, culture    | Systemic erythematous lupus-like disease              | Oral and intra-articular CS, MTX          | Intra-articular injection 2 days before | No         |
| Dugar et al. 2009 [7]       | Male   | 56      | Left foot        | *L. longbeachae* | Culture                  | Rheumatoid arthritis, diabetes mellitus              | Oral CS, MTX                            | Unknown                          | No         |
| Linscott et al. 2004 [8]    | Female | 80      | Right MCP joint  | *L. pneumophila* serogroup 4 | Culture on chocolate agar | No                                                  | Unknown                                | Unknown                          | No         |
| Thurneysen and Boggian 2014 | Male   | 70      | Right knee, Left ankle | *L. pneumophila* serogroup 1 | 16S rRNA PCR, culture | Secondary thymoma- associated immunoglobulin deficiency | No                                      | Unknown                          | Yes, 5 months before |
| Naito et al. 2007 [10]      | Female | 80      | Left and Right ankle | *L. pneumophila* serogroup 1 | Urinary antigen, 16S rRNA PCR | Chronic kidney disease                              | No                                      | Unknown                          | Yes, LD 16 days before |
| Bemer et al. 2002 [11]      | Male   | 51      | Right wrist and ankle, both knees | *L. pneumophila* serogroup 1 | Urinary antigen, Culture on mycobacteria medium | Recurrence of thymoma 1 year before                  | No                                      | Unknown                          | Yes, at the same time |

CS Corticosteroid, LD Legionnaires’ disease, MCP Metacarpophalangeal, MTX Methotrexate, rRNA PCR ribosomal ribonucleic acid polymerase chain reaction
responsible for the vast majority of LD cases worldwide [1]. In contrast with pneumonia, non-Lp1 Legionella strains are predominant among the cases of monoarthritis reported in the literature (Table 1). This particular epidemiology is consistent with the environmental distribution of Legionella strains [12] and the direct mode of transmission from their natural niche; a similar epidemiology has been described for skin and soft tissue Legionella infections [13].

Host response to Legionella infections involves both innate and adaptive immunity [14, 15] and immunosuppressive therapies such as systemic CS, cytotoxic chemotherapy, and biological therapies (i.e. tumor necrosis factor inhibitors) are risk factors for Legionella infections [15–17]. Post-inoculation arthritis were described in patients receiving CS with or without MTX (Table 1), suggesting that inoculated Legionella was not cleared at the first step of infection. Three cases received intra-articular CS that constitutes both a gateway for environmental germs and an additional local risk factor for infection. In the case described herein, the patient also received tocilizumab, an IL-6 receptor antagonist. A case of Lp1 pneumonia in a patient under tocilizumab has been described [18]. As described herein, the patient presented no fever as tocilizumab inhibits IL-6, an inflammation and fever mediator [19], and, by delaying the diagnosis, tocilizumab contributes to uncontrolled infections.

Another clinical feature of Legionella arthritis is polyarthritis occurring during the course or after pneumonia. Interestingly, the reported cases are all due to Lp1 strains that predominate in LD (Table 1) suggesting secondary joint infections after bacterial blood dissemination. Accordingly, cases of Lp1 bacteremia have been described [20–22], and Lindsay et al. reported that up to 80.5% of patients present an Lp1 blood positive PCR after LD onset [23]. Nevertheless, non-Lp1 bacteremias have also been described [24, 25] and no data comparing blood bacterial loads between Lp1 and non-Lp1 strains are available.

In conclusion, the clinical presentation of Legionella arthritis reveals the mode of infection and orientates the microbiological diagnosis towards either Lp1 or non-Lp1. In both contexts, 16S rRNA and Legionella specific PCRs are key factors for the diagnosis.

Abbreviations
CS: Corticosteroid; LD: Legionnaires’ disease; Lp1: Legionella pneumophila serogroup 1; MCP: Metacarpophalangeal; MTX: Methotrexate; rRNA PCR: Ribosomal ribonucleic acid polymerase chain reaction

Acknowledgements
The authors are grateful to Dr. P Robinson for his critical reading of the manuscript.

Authors’ contributions
MI drafted the manuscript. LB made substantial contributions to the analysis and interpretation of the data. HL, AGR, CG participated to acquisition of data. SJ designed the study and reviewed the manuscript for intellectual content. GD designed the study, made substantial contributions to the analysis and interpretation of the data and drafted the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1Hospices Civils de Lyon, Groupement Hospitalier Nord, Institut des Agents Infectieux, Laboratoire de Bactériologie, Lyon, France. 2Hospices Civils de Lyon, Groupement Hospitalier Nord, Institut des Agents Infectieux, Centre National de Référence des Légionelles, Lyon, France. 3Hospices Civils de Lyon, Groupement Hospitalier Sud, Hôpital Lyon Sud, Service de Rhumatologie, Pierre-Bénite, France. 4Hospices Civils de Lyon, Groupement Hospitalier Centre, Hôpital Edouard Herriot, Service de Rhumatologie, Lyon, France. 5CIRI, Centre International de Recherche en Infectiologie, Équipe Pathogénèse des Légionelles, Lyon, France. 6InsERM, U1111, Université Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France. 7Univ Lyon 1, Lyon, France.

Received: 4 June 2019 Accepted: 20 September 2019

Published online: 21 October 2019

References
1. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet. 2016;387:376–85.
2. Gazzano V, Berger A, Benito Y, Freydiere AM, Tristan A, Boisset S, et al. Reassessment of the role of rapid antigen detection tests in diagnosis of invasive group A streptococcal infections. J Clin Microbiol. 2016;54:994–9.
3. Bandelet F, Blaich A, Soleman E, Gaia V, Osthoff M. Septic arthritis due to Legionella cincinnatiensis: case report and review of the literature. Infection. 2017;45:551–5.
4. Just SA, Knudsen JB, Uldum SA, Holt HM. Detection of Legionella bozemanii, a new cause of septic arthritis, by PCR followed by specific culture. J Clin Microbiol. 2012;50:186–2.
5. Fernández-Cruz A, Marín M, Castello L, Usambilaga R, Martín-Rabadán P, Bouza E. Legionella micdadei, a new cause of prosthetic joint infection. J Clin Microbiol. 2011;49:3409–10.
6. Fiendrie M, Jeurissen M, Franssen M, Kwa D, Kaassen C, Vos F. Septic arthritis caused by Legionella dumoffii in a patient with systemic lupus erythematosus-like disease. J Clin Microbiol. 2011;49:746–9.
7. Dugar M, Rankin WA, Rowe E, Smith MD. “My foot hurts”: a flare of rheumatoid arthritis? Med J Aust. 2009;190:392–3.
8. Linscott AJ, Poulter MD, Ward K, Bruckner DA. Legionella pneumophila Serogroup 4 isolated from joint tissue. J Clin Microbiol. 2004;42:1365–6.
9. Thurneysen C, Boggian K. Legionella pneumophila Serogroup 1 septic arthritis with probable endocarditis in an Immunodeficient patient. J Clin Rheumatol. 2014;20:297–8.
10. Naito T, Suda T, Saga K, Horii T, Chida K. Reactive Legionella pneumophila arthritis diagnosed by polymerase chain reaction. Rheumatol Int. 2007;27:415–6.
11. Bemer P, Leautze S, Ninin E, Jarraud S, Raffi F, Druegeon H. Legionella pneumophila arthritis: use of medium specific for mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens. Clin Infect Dis. 2002;35:66–7.
12. Doleans A, Aurell H, Reynolle M, Lina G, Freney J, Vandenesch F, et al. Clinical and environmental distributions of Legionella strains in France are different. J Clin Microbiol. 2004;42:458–60.
13. Padrnos LJ, Blair JE, Kusne S, Dicaudo DJ, Mikhael JR. Cutaneous legionellosis: case report and review of the medical literature. Transpl Infect Dis. 2014;16:307–14.

14. Newton HJ, Ang DKY, Van Driel JR, Hartland EL. Molecular pathogenesis of infections caused by Legionella pneumophila. Clin Microbiol Rev. 2010;23:274–98.

15. Lanterrier F, Ader F, Pilmis B, Catherinot E, Jarraud S, Lortholary O. Legionnaire’s disease in compromised hosts. Infect Dis Clin N Am. 2017;31:123–35.

16. Carratala J, Gudiol F, Pallares R, Dorca J, Verdaguer R, Ariza J, et al. Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med. 1994;149:625–30.

17. Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, et al. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest. 2013;144:990–8.

18. Arinuma Y, Nogi S, Ishikawa Y, Nakayama H, Hashimoto A, Komiya A, et al. Fatal complication of Legionella pneumophila pneumonia in a Tocilizumab-treated rheumatoid arthritis patient. Intern Med. 2015;54:1125–30.

19. Netea MG, Kullberg BJ, Van der Meer JWM. Circulating Cytokines as Mediators of Fever. Clin Infect Dis. 2000;31(Supplement_5):S178–84.

20. Rihs JD, Yu VL, Zuravleff JJ, Goetz A, Muder RR. Isolation of Legionella pneumophila from blood with the BACTEC system: a prospective study yielding positive results. J Clin Microbiol. 1985;22:422–4.

21. Kaku N, Yanagihara K, Morinaga Y, Sato T, Nakashima M, Sakai T, et al. Detection of Legionella pneumophila serogroup 1 in blood cultures from a patient treated with tumor necrosis factor-alpha inhibitor. J Infect Chemother. 2013;19:166–70.

22. Lai CC, Tan CK, Chou CH, Hsu HL, Huang YT, Liao CH, et al. Hospital-acquired pneumonia and bacteremia caused by Legionella pneumophila in an immunocompromised patient. Infection. 2010;38:135–7.

23. Lindsay DSJ, Abraham WH, Findlay W, Christie P, Johnston F, Edwards GFS. Laboratory diagnosis of legionnaires’ disease due to Legionella pneumophila serogroup 1: comparison of phenotypic and genotypic methods. J Med Microbiol. 2004;53:183–7.

24. Moriguchi S, Abe M, Kimura M, Yoshino C, Baba M, Okada C, et al. The diagnosis of Legionella pneumophila Serogroup 5 Bacteremic pneumonia during severe neutropenia using loop-mediated isothermal amplification. Intern Med. 2017;57:1045–8.

25. Cheung YF, Leung MP, Yuen KY. Legionella pneumonia and bacteremia in association with protein-losing enteropathy after Fontan operation. J Inf Secur. 2001;42:206–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.